NCT05816044 is a clinical trial in Pre-Eclampsia, sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization.

Who is sponsoring NCT05816044?

NCT05816044 is sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization.

What condition does NCT05816044 study?

NCT05816044 studies Pre-Eclampsia.

Is NCT05816044 still recruiting?

NCT05816044 is currently completed. Last updated 29 August 2023.

Last reviewed 2023-08-29 · How we verify

NCT05816044

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of HALP Score in Preeclampsia

Completed Last updated 29 August 2023

What this trial tests

trial in Pre-Eclampsia in 300 participants. Completed in 15 July 2023.

Timeline

22 February 2023

Primary endpoint
22 May 2023

15 July 2023

Quick facts

Lead sponsor	Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	22 February 2023
Primary completion	22 May 2023
Estimated completion	15 July 2023
Sites	1 location across Turkey (Türkiye)

Conditions studied

Pre-Eclampsia — all drugs for Pre-Eclampsia →

Sponsor

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Who can join

Adults 18 to 44, female only, with Pre-Eclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preeclampsia is a serious condition that can occur during pregnancy and can pose problems for both the mother and the baby. It occurs in approximately 2-8% of all pregnancies globally and is caused by issues with blood vessels, leading to elevated blood pressure and other related health concerns. Additionally, insufficient nutrition and inflammation within the mother's body may contribute to the development of preeclampsia. The HALP score serves as a tool to assess various elements within the blood, indicating inflammation or inadequate nutrition. Although it has been utilized in other medical contexts, its application during pregnancy remains limited. The HALP score has been employed to predict the emergence of ailments such as heart disease and cancer. Given that preeclampsia can stem from inflammation and poor nutrition, the potential of the HALP score in predicting the likelihood of preeclampsia during pregnancy is being examined through research.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pre-Eclampsia

Currently open trials in the same condition.

NCT07245056 — Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia · NA · recruiting
NCT07187596 — Mortality Outcome of Controlled Hypertension · active not recruiting
NCT06893510 — Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia · NA · recruiting
NCT06122220 — Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia. · NA · recruiting
NCT06779916 — Autophagy/Apoptosis Balance in Placental Vascular Pathologies · recruiting

Other Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization trials

Trials by the same sponsor.

NCT07500285 — Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Ph · Phase 2 · not yet recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07390279 — Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia · recruiting
NCT07357922 — Serum Progesterone and Threatened Abortion During Lactation · not yet recruiting
NCT07283250 — Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05816044 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Last refreshed: 29 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05816044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing